The European Medicines Agency (EMA) recently approved Ontozry (cenobamato) for the treatment of refractory focal epileptic seizures in adults, providing a new therapeutic option for patients who have not responded well to traditional antiepileptic medications.…
April 12, 2025 — In a landmark advancement for rare cancer treatment, Ogsiveo® (nirogacestat) has solidified its position as the first and only FDA-approved therapy for adults with progressing desmoid tumors, a rare and often debilitating soft-tissue condition. Developed by SpringWorks Therapeutics,…
April 12, 2025 — The U.S. Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) as the first and only treatment specifically indicated for myelofibrosis (MF) patients with anemia, marking a significant advancement in managing this rare and debilitating…
On June 6, 2024, the U.S. Food and Drug Administration (FDA) granted approval for Rytelo™ (generic name: imetelstat), developed by Geron Corporation, for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes…
Recently, Qelbree has attracted a lot of attention in the pharmaceutical field.Qelbree focuses on specific attention-related conditions. The development of this drug has been a long and rigorous process, with researchers investing a great deal…
On 15 November 2024, the US Food and Drug Administration (FDA) approved a new drug called Revuforj (revumenib) for the treatment of adult and paediatric patients aged 1 year and older with relapsed or refractory…
Zolgensma (onasemnogene abeparvovec), Novartis’ gene therapy for spinal muscular atrophy (SMA), recently announced landmark long-term follow-up data that children treated with Zolgensma were able to maintain key motor functions after 10 years, with some patients…
The European Commission (EC) has approved an expansion of the indication for the anti-HIV combination drug Rezolsta (dalunavir/cobicistat) for use in adolescents with HIV who are 12 years of age and older and weigh ≥40kg.…
FDA Approval Of Rylaze Fills Asparaginase Shortage Gap, Offers New Hope For ALL/LBL Patients In June 2021, the U.S. Food and Drug Administration (FDA) approved Rylaze (JZP458, recombinant Owenella asparaginase) for the treatment of patients…
Amidst the continuous progress in the field of medicine, Ravicti (glycerol phenylbutyrate), an innovative drug, is bringing new treatment options for patients with urea cycle disorders (UCD). This article explores the background of Ravicti’s development,…
In the medical field, Soliris (eculizumab) is undoubtedly a shining star, which brings unprecedented hope to patients with rare diseases. Let’s take a closer look at the background of the drug’s development, its medical uses,…
Myalepta (generic: metreleptin), the first approved leptin replacement therapy, is offering new hope for these patients. Lipodystrophy is a rare metabolic disorder in which patients suffer from severe metabolic disturbances due to leptin deficiency. Global…
